CN110317257A - 一种辛卡利特的固液相合成法 - Google Patents
一种辛卡利特的固液相合成法 Download PDFInfo
- Publication number
- CN110317257A CN110317257A CN201910474762.8A CN201910474762A CN110317257A CN 110317257 A CN110317257 A CN 110317257A CN 201910474762 A CN201910474762 A CN 201910474762A CN 110317257 A CN110317257 A CN 110317257A
- Authority
- CN
- China
- Prior art keywords
- sincalide
- asp
- fmoc
- phe
- resin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 title claims abstract description 49
- 108010087230 Sincalide Proteins 0.000 title claims abstract description 45
- 229960002959 sincalide Drugs 0.000 title claims abstract description 45
- 239000007791 liquid phase Substances 0.000 title claims abstract description 15
- 238000003786 synthesis reaction Methods 0.000 title claims abstract description 13
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 12
- 239000011347 resin Substances 0.000 claims abstract description 40
- 229920005989 resin Polymers 0.000 claims abstract description 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 16
- KSDTXRUIZMTBNV-INIZCTEOSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)butanedioic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)O)C(O)=O)C3=CC=CC=C3C2=C1 KSDTXRUIZMTBNV-INIZCTEOSA-N 0.000 claims abstract description 15
- 239000012634 fragment Substances 0.000 claims abstract description 13
- 150000001413 amino acids Chemical class 0.000 claims abstract description 10
- 239000012043 crude product Substances 0.000 claims abstract description 10
- 229910006069 SO3H Inorganic materials 0.000 claims abstract description 9
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims abstract description 9
- -1 dichloro triphenyl chlorine Chemical compound 0.000 claims abstract description 8
- 108010016626 Dipeptides Proteins 0.000 claims abstract description 7
- 238000000926 separation method Methods 0.000 claims abstract description 7
- NALWOULWGHTVDA-UWVGGRQHSA-N Asp-Tyr Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NALWOULWGHTVDA-UWVGGRQHSA-N 0.000 claims abstract description 6
- 108010068265 aspartyltyrosine Proteins 0.000 claims abstract description 6
- 238000004108 freeze drying Methods 0.000 claims abstract description 6
- 238000004128 high performance liquid chromatography Methods 0.000 claims abstract description 6
- 238000005520 cutting process Methods 0.000 claims abstract description 4
- 238000010532 solid phase synthesis reaction Methods 0.000 claims abstract description 4
- 238000007670 refining Methods 0.000 claims abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 21
- 238000006243 chemical reaction Methods 0.000 claims description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 235000001014 amino acid Nutrition 0.000 claims description 9
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- BUBGAUHBELNDEW-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylsulfanylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCSC)C(O)=O)C3=CC=CC=C3C2=C1 BUBGAUHBELNDEW-SFHVURJKSA-N 0.000 claims description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- 230000009514 concussion Effects 0.000 claims description 4
- 229910001873 dinitrogen Inorganic materials 0.000 claims description 4
- 230000002101 lytic effect Effects 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- MGHMWKZOLAAOTD-DEOSSOPVSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(1h-indol-3-yl)propanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(=O)O)CC1=CNC2=CC=CC=C12 MGHMWKZOLAAOTD-DEOSSOPVSA-N 0.000 claims description 3
- SWZCTMTWRHEBIN-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=C(O)C=C1 SWZCTMTWRHEBIN-QFIPXVFZSA-N 0.000 claims description 3
- OCCFRTKCROFJLW-NRFANRHFSA-N 4-o-tert-butyl 1-o-(2,5-dioxopyrrolidin-1-yl) (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)butanedioate Chemical compound O=C([C@@H](NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)OC(C)(C)C)ON1C(=O)CCC1=O OCCFRTKCROFJLW-NRFANRHFSA-N 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 150000003053 piperidines Chemical class 0.000 claims description 3
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 239000007787 solid Substances 0.000 abstract description 2
- 239000007858 starting material Substances 0.000 abstract description 2
- 238000010189 synthetic method Methods 0.000 abstract description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 210000000232 gallbladder Anatomy 0.000 description 4
- 101800001982 Cholecystokinin Proteins 0.000 description 3
- 102100025841 Cholecystokinin Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940107137 cholecystokinin Drugs 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 102100021277 Beta-secretase 2 Human genes 0.000 description 2
- 101710150190 Beta-secretase 2 Proteins 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- HSOKCYGOTGVDHL-KRWDZBQOSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methoxy-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OC)C(O)=O)C3=CC=CC=C3C2=C1 HSOKCYGOTGVDHL-KRWDZBQOSA-N 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 229920003180 amino resin Polymers 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical class ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/595—Gastrins; Cholecystokinins [CCK]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及一种辛卡利特固液相结合的合成方法,主要解决现有技术存在的原料昂贵以及后处理繁琐的技术问题。技术方案为:一种辛卡利特的固液相合成法,包括以下步骤:(1)液相法合成Fmoc‑Asp‑Phe‑CONH2二肽片段;(2)将二肽片段装载到二氯三苯基氯树脂上,得到Fmoc‑Asp(β‑2Cl‑Trt Cl树脂)‑Phe‑NH2;(3)固相合成法依次连接余下保护氨基酸,得到辛卡利特树脂肽,Asp‑Tyr(SO3H)‑Met‑Gly‑Trp‑Met‑Asp(β‑2Cl‑Trt Cl树脂)‑Phe‑CONH2;(4)切割得到辛卡利特粗品,Asp‑Tyr(SO3H)‑Met‑Gly‑Trp‑Met‑Asp‑Phe‑CONH2;粗品再经高效液相色谱分离纯化、冻干精制得到辛卡利特。
Description
技术领域
本发明涉及多肽化合物合成技术领域,尤其涉及一种辛卡利特的固液相合成法。
背景技术
胆囊收缩素(CCK)是一种具有多种分子形式且具有双重分布的脑肠肽,由33 个氨基酸组成,具有激素和神经递质的作用。辛卡利特(sincalide)为一八肽分子,是胆囊收缩素的一个片段,具有胆囊收缩素的全部生物活性,是一种人工合成的胆囊素八肽(Octapeptide),主要用于促胆囊收缩,胆囊诊断试剂,临床用于治疗慢性胰腺炎,发现胰分泌功能明显改善,症状明显减轻。CAS 号为:25126-32-3,分子式为C49H62N10O16S3,分子量1143.27。
目前,辛卡利特的制备方法主要有酶法和化学法两种。其中,酶法合成由于涉及酶制剂种类比较多、酶制剂价格昂贵,且中间产物分离困难、制备周期长,目前已不再使用酶法制备辛卡利特。化学合成是目前常用的辛卡利特制备方法。CN201410105423.X公开了一种制备辛卡利特的方法,该方法中选择了氨基树脂,在低温条件下用三氟乙酸裂解多肽树脂,虽然能减少磺酰基脱落,但是不能完全避免,而且会导致多肽裂解不完全,降低粗品收率;CN200810043920.6公开了一种制备辛卡利特的方法,该方法选择用氨水裂解多肽树脂,其中氨水有毒,对眼、鼻、皮肤有刺激性和腐蚀性,不利于后期产业化,而且选用的Fmoc-Asp(odmab)-OH这一原料价格昂贵,增加了生产成本,没有显著的经济效益。CN201810365226.X公开了一种制备辛卡利特的方法,该方法也是选取了两肽片段树脂作为起始树脂,但是Asp1选择了Fmoc-Asp (Ome)-OH保护策略,在裂解后还需要水解去除Ome。
发明内容
本发明的目的在于提供一种高收率、低成本、反应条件温和、环境污染小、有利于实现产业化的辛卡利特的合成方法,主要解决现有技术存在的原料昂贵以及后处理繁琐的技术问题。
本发明的技术方案为:一种辛卡利特的固液相合成法,包括以下步骤:
(1)液相法合成Fmoc-Asp-Phe-CONH2二肽片段;
(2)将二肽片段装载到二氯三苯基氯树脂上,得到Fmoc-Asp(β-2Cl-Trt Cl 树脂)-Phe-NH2;
(3)固相合成法依次连接余下保护氨基酸,得到辛卡利特树脂肽,
Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp(β-2Cl-Trt Cl树脂)-Phe-CONH2;
(4)切割得到辛卡利特粗品,Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-CONH2;粗品再经高效液相色谱分离纯化、冻干精制得到辛卡利特。
具体步骤如下:
(1)Fmoc-Asp(Otbu)-Osu,NH2-Phe-CONH2溶于四氢呋喃中,加入DIEA,搅拌反应2小时,旋蒸除去四氢呋喃,加入体积比95%TFA溶液搅拌反应1-2小时,去除叔丁基,再加乙醚结晶得到Fmoc-Asp- Phe-CONH2二肽片段;
(2)将二氯三苯基氯树脂置于圆底烧瓶中,加入Fmoc-Asp-Phe-CONH2二肽片段,加入二氯甲烷,DIEA,搅拌反应2小时,再加入甲醇震荡反应30分钟,过滤除去滤液;用二氯甲烷洗涤树脂三次,干燥,得到Fmoc-Asp(β-2Cl-Trt Cl 树脂)-Phe-CONH2;
(3)将Fmoc-Asp(β-2Cl-Trt Cl 树脂)-Phe-CONH2置于多肽反应器中,加入脱保护试剂,氮气搅拌反应30分钟,抽干,再用DMF洗涤5次,加入相应的保护氨基酸,HBTU/NMM为缩合剂,DMF做溶剂,反应30-60分钟,茚三酮检测反应终点,反应结束后抽真空排干反应液,用DMF洗涤3次,再加入脱保护试剂,依次循环,直至连完最后一个天冬氨酸,脱保护,得到辛卡利特树脂肽;
脱保护试剂为体积比20%哌啶/DMF溶液,反应中所提到保护氨基酸依次是Fmoc-Met-OH,Fmoc-Trp-OH,Fmoc-Gly-OH,Fmoc-Met-OH,Fmoc-Tyr(SO3h)-OH,Fmoc-Asp(Ofm)-OH;
(4)将辛卡利特树脂肽置于圆底烧瓶中,加入裂解试剂,常温条件下反应1小时,抽滤滤去树脂颗粒,收集滤液,减压浓缩旋去溶剂,得到辛卡利特中间体;再经高效液相色谱分离纯化、冻干后得到辛卡利特精品。
裂解试剂的配比为醋酸:三氟乙酸/二氯甲烷=2/98(V/V);
本发明中一些常用缩写具有以下含义:
HBTU:O-苯并三唑-N,N,N,N-四甲基脲鎓六氟磷酸盐;
NMM:N-甲基吗啉;
Fmoc:芴甲氧羰基;
Trp:色氨酸;
Gly:甘氨酸;
Asp:天冬氨酸;
Phe:苯丙氨酸;
Met:蛋氨酸;
Tyr:酪氨酸;
HSO3:磺酰基;
Ofm:芴甲氧基;
DIEA:N,N-二异丙基乙胺;
DMF:N,N-二甲基甲酰胺;
2Cl-Trt Cl Resin:二氯三苯基氯树脂。
本发明的有益效果是:本发明中策略性的选择了一个二肽片段中的Asp侧链羧基装载到二氯树脂上,在弱酸条件下就能将多肽从树脂上切割下来,避免了强酸条件下磺酸基掉落的副反应,同时Asp1选择Fmoc-Asp(ofm)-OH保护,去Fmoc过程中一并脱除ofm保护基;省去了一个反应步骤,提高了粗品纯度,通过一步切割就得到辛卡利特粗品,该方法操作简单,反应条件温和,无毒害,收率高,并解决了水解过程中产生的废水问题,利于后期工业化放大,具有极大的应用价值。
附图说明
图1为本发明产物色谱图。
图2为本发明产物质谱图。
具体实施方式
以下将参照实例对本发明做进一步的详细描述,但本发明不限于这具体实例。
实施例
(1)制备Fmoc-Asp-Phe-CONH2
称取Fmoc-Asp (Otbu)-OSU 10.2g(MW:508.5,20mmol),NH2-Phe-CONH2 3.61g(MW:164.2,22mmol)加入200ml四氢呋喃,10mlDIEA,搅拌反应2小时,再经萃取,洗涤,旋蒸除去溶剂,得到油状物12.1g,再加入100ml 配比为95%TFA/5%H2O(V/V)去保护基,搅拌反应1-2小时,加乙醚结晶,抽滤除去滤液,得到白色固体滤饼即为二肽片段Fmoc-Asp-Phe-CONH2 ,干燥后得到二肽片段10.5g。
(2)制备Fmoc-Asp(β-2Cl-Trt Cl 树脂)-Phe-CONH2
称取二氯三苯基氯树脂20g,加入Fmoc-Asp-Phe-CONH2 10.5g(MW:501.5,20mmol),加入300ml二氯甲烷,30mlDIEA,搅拌反应2小时,加入200ml甲醇,震荡反应30分钟,过滤除去滤液,树脂用二氯甲烷洗涤3次,得到Fmoc-Asp(β-2Cl-Trt Cl 树脂)-Phe-CONH2;
(3)制备辛卡利特树脂肽
将Fmoc-Asp(β-2Cl-Trt Cl 树脂)-Phe-CONH2置于多肽反应器中,加入300ml脱保护试剂,氮气搅拌反应30分钟,抽干,DMF洗涤5次,称取保护氨基酸,缩合剂,加入到反应器中,再加入200mlDMF,氮气搅拌反应30-60分钟,茚三酮检测反应终点,反应结束后排干反应液,DMF洗涤3次,反复循环,直至连完最后一个氨基酸,脱保护,得到辛卡利特树脂肽;
每一步缩合反应所加入的氨基酸的量分别为:
Fmoc-Met-OH (7.42g),
Fmoc-Trp-OH (8.52g),
Fmoc-Gly-OH(5.95g),
Fmoc-Met-OH(7.43g),
Fmoc-Tyr(SO3H)-OH(9.66g),
Fmoc-Asp(Ofm)-OH(10.67g);
每一步缩合反应所采用的缩合剂的量为:HBTU(3.6g),NMM(2.27ml)
脱帽试剂为体积比20%的哌啶/DMF混合溶液;
(4)制备辛卡利特
取步骤(3)中的辛卡利特树脂肽共32g置于500ml圆底烧瓶中,加入320ml裂解液,配比为三氟乙酸/二氯甲烷=2/98(V/V),置于摇床中常温震荡反应1小时,抽滤滤掉树脂颗粒,收集滤液,减压浓缩旋去溶剂,得到辛卡利特粗品共11.5g;再经高效液相色谱分离纯化、冻干后得到纯度99%的辛卡利特精品7.6g,收率达到66%。见图1、2。
Claims (7)
1.一种辛卡利特的固液相合成法,其特征在于:包括以下步骤
(1)液相法合成Fmoc-Asp-Phe-CONH2二肽片段;
(2)将二肽片段装载到二氯三苯基氯树脂上,得到Fmoc-Asp(β-2Cl-Trt Cl 树脂)-Phe-NH2;
(3)固相合成法依次连接余下保护氨基酸,得到辛卡利特树脂肽,
Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp(β-2Cl-Trt Cl树脂)-Phe-CONH2;
(4)切割得到辛卡利特粗品,Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-CONH2;粗品再经高效液相色谱分离纯化、冻干精制得到辛卡利特。
2.根据权利要求1所述的一种辛卡利特的固液相合成法,其特征在于:步骤(1)具体内容为:Fmoc-Asp(Otbu)-Osu,NH2-Phe-CONH2溶于四氢呋喃中,加入DIEA,搅拌反应2小时,旋蒸除去四氢呋喃,加入体积比95%TFA溶液搅拌反应1-2小时,去除叔丁基,再加乙醚结晶得到Fmoc-Asp- Phe-CONH2二肽片段。
3.根据权利要求1所述的一种辛卡利特的固液相合成法,其特征在于:步骤(2)具体内容为:将二氯三苯基氯树脂置于圆底烧瓶中,加入Fmoc-Asp-Phe-CONH2二肽片段,加入二氯甲烷,DIEA,搅拌反应2小时,再加入甲醇震荡反应30分钟,过滤除去滤液;用二氯甲烷洗涤树脂三次,干燥,得到Fmoc-Asp(β-2Cl-Trt Cl 树脂)-Phe-CONH2。
4.根据权利要求1所述的一种辛卡利特的固液相合成法,其特征在于:步骤(3)具体内容为:将Fmoc-Asp(β-2Cl-Trt Cl 树脂)-Phe-CONH2置于多肽反应器中,加入脱保护试剂,氮气搅拌反应30分钟,抽干,再用DMF洗涤5次,加入相应的保护氨基酸,HBTU/NMM为缩合剂,DMF做溶剂,反应30-60分钟,茚三酮检测反应终点,反应结束后抽真空排干反应液,用DMF洗涤3次,再加入脱保护试剂,依次循环,直至连完最后一个天冬氨酸,脱保护,得到辛卡利特树脂肽。
5.根据权利要求4所述的一种辛卡利特的固液相合成法,其特征在于:脱保护试剂为体积比20%哌啶/DMF溶液,反应中所提到保护氨基酸依次是Fmoc-Met-OH,Fmoc-Trp-OH,Fmoc-Gly-OH,Fmoc-Met-OH,Fmoc-Tyr(SO3h)-OH,Fmoc-Asp(ofm)-OH。
6.根据权利要求1所述的一种辛卡利特的固相合成法,其特征在于:步骤(4)具体内容为:将辛卡利特树脂肽置于圆底烧瓶中,加入裂解试剂,常温条件下反应1小时,抽滤滤去树脂颗粒,收集滤液,减压浓缩旋去溶剂,得到辛卡利特中间体;再经高效液相色谱分离纯化、冻干后得到辛卡利特精品。
7.根据权利要求6所述的一种辛卡利特的固液相合成法,其特征在于:所述裂解试剂为下述体积比的混合物:三氟乙酸:二氯甲烷=2:98。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910474762.8A CN110317257B (zh) | 2019-06-03 | 2019-06-03 | 一种辛卡利特的固液相合成法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910474762.8A CN110317257B (zh) | 2019-06-03 | 2019-06-03 | 一种辛卡利特的固液相合成法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110317257A true CN110317257A (zh) | 2019-10-11 |
CN110317257B CN110317257B (zh) | 2023-10-31 |
Family
ID=68119239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910474762.8A Active CN110317257B (zh) | 2019-06-03 | 2019-06-03 | 一种辛卡利特的固液相合成法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110317257B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111233714A (zh) * | 2020-03-18 | 2020-06-05 | 滨海吉尔多肽有限公司 | 一种maps多肽的制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1210543A (zh) * | 1996-02-09 | 1999-03-10 | 霍夫曼-拉罗奇有限公司 | 血管活性肠肽类似物的合成 |
CN101463072A (zh) * | 2008-11-11 | 2009-06-24 | 吉尔生化(上海)有限公司 | 一种八肽胆囊收缩素的制备方法 |
CN102775471A (zh) * | 2012-08-03 | 2012-11-14 | 吉尔生化(上海)有限公司 | 固相法和液相法结合合成八肽胆囊收缩素的方法 |
CN103833842A (zh) * | 2014-03-20 | 2014-06-04 | 深圳翰宇药业股份有限公司 | 一种辛卡利特的制备方法 |
CN104987362A (zh) * | 2015-07-20 | 2015-10-21 | 合肥国肽生物科技有限公司 | 一种固相合成制备醋酸辛卡利特的方法 |
CN106397572A (zh) * | 2016-10-24 | 2017-02-15 | 合肥国肽生物科技有限公司 | 一种辛卡利特的纯化方法 |
CN108239148A (zh) * | 2018-04-23 | 2018-07-03 | 滨海吉尔多肽有限公司 | 一种辛卡利特的固相合成法 |
-
2019
- 2019-06-03 CN CN201910474762.8A patent/CN110317257B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1210543A (zh) * | 1996-02-09 | 1999-03-10 | 霍夫曼-拉罗奇有限公司 | 血管活性肠肽类似物的合成 |
CN101463072A (zh) * | 2008-11-11 | 2009-06-24 | 吉尔生化(上海)有限公司 | 一种八肽胆囊收缩素的制备方法 |
CN102775471A (zh) * | 2012-08-03 | 2012-11-14 | 吉尔生化(上海)有限公司 | 固相法和液相法结合合成八肽胆囊收缩素的方法 |
CN103833842A (zh) * | 2014-03-20 | 2014-06-04 | 深圳翰宇药业股份有限公司 | 一种辛卡利特的制备方法 |
CN104987362A (zh) * | 2015-07-20 | 2015-10-21 | 合肥国肽生物科技有限公司 | 一种固相合成制备醋酸辛卡利特的方法 |
CN106397572A (zh) * | 2016-10-24 | 2017-02-15 | 合肥国肽生物科技有限公司 | 一种辛卡利特的纯化方法 |
CN108239148A (zh) * | 2018-04-23 | 2018-07-03 | 滨海吉尔多肽有限公司 | 一种辛卡利特的固相合成法 |
Non-Patent Citations (2)
Title |
---|
凌云等: "八肽胆囊收缩素(CCK-8)的合成及其药理评价", 《中国药物化学杂志》 * |
武振羽等: "环肽合成进展", 《化学进展》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111233714A (zh) * | 2020-03-18 | 2020-06-05 | 滨海吉尔多肽有限公司 | 一种maps多肽的制备方法 |
CN111233714B (zh) * | 2020-03-18 | 2022-04-08 | 滨海吉尔多肽有限公司 | 一种maps多肽的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN110317257B (zh) | 2023-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101357936B (zh) | 固相多肽合成曲普瑞林的制备方法 | |
CN107434820A (zh) | 一种维拉卡肽的合成方法 | |
CN102260326A (zh) | 卡贝缩宫素的制备方法 | |
CN109836455B (zh) | 基于磷或亚磷酰氧基二苯甲醇及其衍生物及辅助的胸腺五肽液相合成方法 | |
CN110317257A (zh) | 一种辛卡利特的固液相合成法 | |
CN109280078B (zh) | 一种制备维拉卡肽的方法 | |
CN108239148A (zh) | 一种辛卡利特的固相合成法 | |
CN112585153B (zh) | 一种化合物或其盐及其制备方法与应用 | |
CN1865282B (zh) | 固相多肽合成特利加压素的制备方法 | |
CN108003222A (zh) | 一种普利卡那肽的固相合成方法 | |
CN110922453B (zh) | 一种戈舍瑞林的合成方法 | |
CN109354608A (zh) | 一种基于Fmoc二肽的合成阿拉瑞林的方法 | |
CN107629111A (zh) | 一种乙酰基四肽‑2的液相合成方法 | |
CN111944016B (zh) | 一种醋酸艾替班特的制备方法 | |
KR101574252B1 (ko) | 고체상 펩타이드 합성법을 이용한 신규한 탈티렐린의 제조 방법 | |
CN111285921B (zh) | Bdk辅助基团及基于bdk辅助基团的普卡那肽及类似物的液相全合成方法 | |
CN107778350A (zh) | 一种合成罗米地辛的方法 | |
CN113045641A (zh) | 一种索马鲁肽的制备方法 | |
EP0277561B1 (en) | New arginine derivative, process for the preparation thereof and its use in peptide synthesis | |
CN110256532A (zh) | 一种rgd环肽合成方法 | |
CN104447979B (zh) | 一种制备奈西利肽的方法 | |
CN107987123B (zh) | 一种十四烷基氨基丁酰缬氨酰胺基丁酸脲三氟乙酸盐的液相合成方法 | |
WO2020125045A1 (zh) | 一种罗米地辛的合成方法 | |
CN110386964A (zh) | 一种亮丙瑞林的固液合成方法 | |
CN108752416A (zh) | 氨基酸多肽的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |